Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

Cellceutix advancing as a mid stage biopharmaceutical company. Developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications.

http://cellceutix.com/#sthash.KFVdEjVL.dpbs





Kevetrin
http://cellceutix.com/kevetrin/#sthash.QFsdWdud.dpbs

Brilacidin-OM Oral Mucositis - See more at: http://cellceutix.com/brilacidin-om/#sthash.pL7VHg0p.dpuf

Brilacidin
http://cellceutix.com/brilacidin/#sthash.93hfY1qy.dpbs

Prurisol
http://cellceutix.com/prurisol/#sthash.xaGF4yGk.dpbs

Events/Presentations
http://cellceutix.com/events/#sthash.uBEPOeUW.dpbs


FULL 100% SEC filer...
https://www.sec.gov/cgi-bin/browse-edgar?company=cellceutix&owner=exclude&action=getcompany


An ever quickening pace of achievement....

K= kevetrin B= brilacidin P= prurisol

CTIX Clinicals, FDA, Milestones

Cellceutix clinical trials...
https://clinicaltrials.gov/ct2/results?term=cellceutix&Search=Search

10/5/12 K Ph1 starts

10/9/13 Acquired Poly assets

2/24/14 B/ABSSSI Ph2b starts

3/24/14 P Ph1 crossover study starts

8/7/14 B/ABSSSI meets Ph2b endpoints

10/13/14 B/OM Ph2 approval to commence

12/10/14 B/ABSSSI granted QIDP designation

12/10/14 P Ph2 start approved by FDA

5/22/15 K Ph1 allowed additional patient enrollment

7/20/15 K granted OrphanDrug Designation for Ovarian cancer

8/6/15 P Ph2 commences

11/23/15 K for Retinoblastoma (eye cancer) receives OrphanDrug Designation

11/25/15 B/OM granted FDA Fast Track Designation

12/1/15 K granted "Rare Pediatric Disease Designation" for Retinoblastoma

1/21/16 K receives Orphan Drug (FDA) Designation for Pancreatic Cancer
Applying for grants with research partner ?Mayo Clinic?

2/10/16 K approved for Ph2 ovarian cancer trial

2/16/16 K Ph1 trial formally concludes

2/22/16 K Ph1 early data-Increased p21 Expression in 67.5% of Evaluable Patients

3/17/16 P ph2 last patient dosed

5/31/16 P ph2 successful trial data released

6/9/16 K ph1 hard lock of data

6/10/16 Rosen/scam lawsite dismissed by court.

6/15/16 Ph 2 Trial of Brilacidin as a Novel Therapy for Ulcerative Proctitis... patients have been screened and the administration of Brilacidin to patients is expected to begin this week in the Phase 2 Proof of Concept trial of Brilacidin for the treatment of ulcerative proctitis.
- See more at: http://cellceutix.com/cellceutix-starts-phase-2-trial-of-brilacidin-as-a-novel-therapy-for-ulcerative-proctitis/#sthash.Ts70jjtA.dpuf

7/18/19 Cellceutix Receives Update on First Patient Enrolled in Phase 2 Proof-of-Concept Study of Brilacidin for Ulcerative Proctitis Company Encouraged by Investigator Report of Significant Decrease in Symptoms in First Patient in One Week
- See more at: http://cellceutix.com/cellceutix-receives-update-on-first-patient-enrolled-in-phase-2-proof-of-concept-study-of-brilacidin-for-ulcerative-proctitis/#sthash.WL2sAfEh.dpuf

=========================================================



Events and Presentations

“Dermatology Overview” – July 8, 2016

http://cellceutix.com/wp-content/uploads/2014/06/Cellceutix_Corporate_Slide-Deck_DERMATOLOGY-Non-Confidential-July-2016-1-1.pdf



American Society for Microbiology – 2016

Boston, MA. June 16-20, 2016

Antifungal Potential of Peptide Mimetics in a Mouse Model of Invasive Candidiasis
http://cellceutix.com/wp-content/uploads/2014/06/ASM-Boston-Conference-FINAL1.pdf


American Society for Microbiology – 2016

Boston, MA. June 16-20, 2016

Application of Pharmacokinetic-Pharmacodynamic Models for Brilacidin Dose Selection Support for Patients with Acute Bacterial Skin and Skin Structure Infections

http://cellceutix.com/wp-content/uploads/2014/06/Application-of-Pharmacokinetic-Pharmacodynamic-Models-for-Brilacidin-Dose-Selection-Support-for-Patients-with-Acute-Bacterial-Skin-and-Skin-Structure-Infections-.pdf


American Society for Microbiology – 2016

Boston, MA, June 16-20, 2016

Activity of Potent and Selective Host Defense Peptide Mimetics in Mouse Models of Oral Candidiasis

http://cellceutix.com/wp-content/uploads/2014/06/Antimicrob.-Agents-Chemother.-2014-Ryan-3820-7.pdf

========================================

Some Due Diligence on B-UP Trial Design
Posted by sox040713 Monday, 07/18/16 12:53:34 PM

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123946868